CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 176 enrolled
Drug / intervention
MEDI4736 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02318277
NCT02318277Phase 2Completed
CompareCT.gov

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Incyte Corporation·interventional·Posted Dec 17, 2014·Updated Jan 13, 2022

In Brief

A Phase 2 clinical trial evaluating MEDI4736 and INCB024360 for Solid Tumors and 3 related conditions. Completed, enrolled 176 participants across 13 sites.

Detailed Summary

The purpose of this study is to explore the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of INCB024360 administered in combination with MEDI4736 in subjects with selected advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors, Head and Neck Cancer, Lung Cancer, UC (Urothelial Cancer)
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 17, 2014
Enrollment StartJan 5, 2015
Primary CompletionAug 28, 2019
Study CompletionOct 16, 2020
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 11.5 years ago

Interventions

MEDI4736drug

MEDI4736 administered intravenously (IV) every two weeks (q2w)

INCB024360drug

INCB024360: Oral daily dosing